Dr. Reddy’s Global CEO Leads Delegation to Hybio, Mapping Out International Peptide Partnership
On September 23rd, Erez Israeli, Global Chief Executive Officer of Dr. Reddy’s Laboratories (a world-renowned pharmaceutical enterprise), led a senior executive team to visit the Shenzhen headquarters of Hybio Pharmaceutical Co., Ltd. (hereinafter referred to as "Hybio Pharmaceutical"). The two parties conducted in-depth exchanges on topics such as Peptide Drug research and development, global commercial layout, and potential strategic cooperation possibilities. Shaogui Zeng, Chairman and President of Hybio Pharmaceutical, led the core management team to warmly receive the visitors and participate in the discussion.
The 12member delegation from Dr. Reddy’s included Ramana MV, Chief Executive Officer of Brand Markets (India and Emerging Markets) etc. Leaders from Hybio Pharmaceutical who attended the discussion included Pauline Yu, Executive President, Yangming Tang, Vice President, and Joanna Yeung, Vice President, etc.
During the vist, accompanied by Hybio Pharmaceutical’s senior executives, the Dr. Reddy’s delegation visited the company’s Wuhan Active Pharmaceutical Ingredient (API) base, Pingshan Pharmaceutical Preparation Production Base, headquarters R&D center, and product exhibition hall. They gained a detailed understanding of Hybio Pharmaceutical’s achievements and capabilities in peptidedrugR&D,largescale production, quality management systems, and international registration. Hybio Pharmaceutical’s quality management system, which strictly adheres to cGMP, FDA, and EU GMP standards, left a deep impression on the delegation.
In the subsequent meeting, Mr. Shaogui Zeng, Chairman and President of Hybio Pharmaceutical, systematically introduced Hybio Pharmaceutical’s development strategy and core advantages. As an advanced enterprise with 27 years of experience in the peptide industry, Hybio Pharmaceutical has achieved fruitful results in fields such as peptide preparations and peptide APIs. It has built a complete industrial chain covering everything from target discovery to commercial production, with API products sold in more than 20 countries and finished dosage drugs licenseout to approx. 90 regions worldwide. Its R&D progress in innovative drug fields such as GLP-1R/GIPR/GCGR triple agonists is at the forefront of the industry. He stated, "We are honored to welcome the visit of a global pharmaceutical enterprise like Dr. Reddy’s. Dr. Reddy’s strong commercial network and rich experience in emerging and mature markets are highly complementary to Hybio Pharmaceutical’s leading R&D and manufacturing capabilities. This exchange marks a good start for both parties to build mutual trust and explore a win-win cooperation model. We look forward to working with Dr. Reddy’s to bring more high-quality pharmaceutical products to the global market and benefit a wider range of patient groups."
Erez Israeli, Global Chief Executive Officer of Dr. Reddy’s - whose branded generics, innovative branded medicines and APIs already reach more than 120 countries—also said, "We are deeply impressed by Hybio Pharmaceutical’s professionalism and innovative strength in the peptide drug field. This visit has enhanced our understanding of Hybio Pharmaceutical, and we have seen many alignments between our two parties’ values and strategic goals. We look forward to maintaining close communication with the Hybio Pharmaceutical team and in-depth discussions on specific cooperation opportunities."
Dr. Reddy’s visit this time not only recognizes Hybio Pharmaceutical’s comprehensive strength but also injects new momentum into accelerating the layout of its internationalization strategy. In the future, Hybio Pharmaceutical will continue to uphold an open and cooperative attitude, join forces with international partners, and achieve resource sharing and win-win cooperation.
About Hybio Pharma
An A-share listed, state-level high-tech enterprise dedicated to the R&D, manufacturing, and marketing of innovative medicines. With over 20 years of focus on peptide therapeutics, Hybio Pharma has built a comprehensive formulation pipeline covering the world’s major peptide targets. Its portfolio includes first-in-class triple agonists for GLP-1R/GIPR/GCGR, as well as global blockbuster peptide ANDA products such as retatrutide, tirzepatide, semaglutide, and liraglutide. Hybio Pharma owns nearly 500 granted patents at home and abroad and was the first company worldwide to receive U.S. FDA approval for a generic daily GLP-1 Liraglutide Injection. Its products are already marketed in the regulated markets of Europe and the United States.
About Dr. Reddy’s
A major Indian pharmaceutical company headquartered in Hyderabad, founded in 1984, Dr. Reddy’s Laboratories is a vertically integrated multinational dedicated to providing affordable, innovative medicines that improve human health. Through its end-to-end value chain, Dr. Reddy’s supplies active pharmaceutical ingredients (APIs), generic drugs, biosimilars, differentiated formulations, and new chemical entities (NCEs), together with a broad range of custom pharmaceutical services.